TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24210549
Drug: Apparent treatment-resistant
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apparent treatment-resistant hypertension
Study: 22440192
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 8 mg and amlodipine besilate 5 mg (CC/AML 8/5 mg)
Study: 22440192
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 8 mg (CC 8 mg)
Study: 22440192
Drug: Amlodipine besilate
Normalized name: Amlodipine besilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine besilate 5 mg (AML 5 mg)
Study: 20632489
Drug: Routine methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine methods and topical oxygen therapy (Group B)
Study: 20632489
Drug: Routine methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine methods and bFGF therapy (Group C)
Study: 20632489
Drug: Routine methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine methods and bFGF/topical oxygen therapy (Group D)
Study: 17717526
Drug: Alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 10 mg once daily (q.d.)
Study: 16297757
Drug: Butorphanol (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (0.02 mg/kg)
Study: 11905429
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (10 units)
Study: 11905429
Drug: Intramuscular syntometrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular syntometrine (1 ml)
Study: 10707131
Drug: 0.25 ml
Normalized name: mineral oil 0.25 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 ml of Mydricaine No. 1
Study: 8944370
Drug: Mesalazine 500
Normalized name: mesalazine 500 Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine 500 mg thrice daily for 7 days
Study: 8944370
Drug: Olsalazine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine 500 mg twice daily for 7 days
Study: 31961224
Drug: Bevacizumab (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (2.5 mg) - three intravitreal injections at monthly intervals
Study: 31961224
Drug: Triamcinolone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone (8 mg) - single injection followed by two sham interventions at monthly intervals
Study: 22397239
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ramipril and valsartan (N = 26)
Study: 22397239
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ramipril + valsartan)
Study: 22397239
Drug: Monotherapy (ramipril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (ramipril or valsartan)
Study: 17509426
Drug: N-acetylcysteine (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (twice per day dosing regimen: one dose before and three doses after contrast media exposure)
Study: 17509426
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice per day dosing regimen: one dose before and three doses after contrast media exposure)
Study: 14715839
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg melatonin daily for 4 weeks
Study: 14715839
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg melatonin daily for 4 weeks (second study)
Study: 9368234
Drug: intensive oral
Normalized name: Uricalm Intensive Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: intensive oral + i.v. magnesium supplementation
Study: 1609935
Drug: Bolus plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus plus infusion (4 ml incremental bolus with 15 minute lockout, plus a 4 ml per hour infusion of 0.125% bupivacaine plus fentanyl 3 mcg per ml)
Study: 1609935
Drug: Bolus only
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus only (4 ml incremental bolus with 15 minute lockout of 0.125% bupivacaine plus fentanyl 3 mcg per ml)
Study: 3594511
Drug: Clopamide monotherapy
Normalized name: clopamide
DrugBank: Clopamide (DB13792)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopamide monotherapy
Study: 363480
Drug: Pindolol monotherapy
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol monotherapy
Study: 3594511
Drug: Combined pindolol-clopamide
Normalized name: clopamide / pindolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined pindolol-clopamide therapy
Study: 26043562
Drug: Wuling Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuling Capsule (0.33 g/capsule, 3 times per day) + Pinaverium Bromide (50 mg/tablet, 3 times per day)
Study: 26043562
Drug: Pinaverium Bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium Bromide (50 mg/tablet, 3 times per day)
Study: 26043562
Drug: Wuling Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuling Capsule + Pinaverium Bromide
Study: 23829154
Drug: Caffeine gum
Normalized name: caffeine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine gum (100 mg)
Study: 14623808
Drug: Adenosine (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (0.125 mg/min)
Study: 14623808
Drug: Adenosine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (0.5 mg/min)
Study: 14623808
Drug: Dipyridamole (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (loading dose, 0.142 mg/kg per min for 5 minutes followed by 0.004 mg/kg per min)
Study: 10632647
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg o.d. for the first 6 days (PAAz group; n=55)
Study: 10632647
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg b.d. for the first 7 days (PAC group; n=55)
Study: 3987798
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of cefuroxime (250 mg) in patients with peritonitis
Study: 3987798
Drug: Intraperitoneal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal administration of cefuroxime (250 mg) in patients with peritonitis
Study: 3987798
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of cefuroxime (250 mg) in uninfected patients
Study: 3987798
Drug: Intraperitoneal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal administration of cefuroxime (250 mg) in uninfected patients
Study: 29330176
Drug: Guided physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided physical exercise and dietary therapy programme (PED‐t)
Study: 25377395
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and 0.15 mg/kg ketamine (group 1)
Study: 25377395
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and 0.3 mg/kg ketamine (group 2)
Study: 25377395
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and normal saline placebo (standard care group)
Study: 23718080
Drug: 2% procaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% procaine solution administered via electrophoresis and mesotherapy
Study: 23718080
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via galvanization and mesotherapy
Study: 18226669
Drug: Monophasic combination
Normalized name: Monobasic Potassium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic combination oral contraceptive (COC)
Study: 9180855
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 30 mg/day for 5 years
Study: 1286499
Drug: Flumazenil (0.89
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.89 mg IV, range: 0.4 mg to 1 mg)
Study: 3812947
Drug: Intramuscular nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular nalbuphine 20 mg
Study: 26446253
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg nightly
Study: 25703411
Drug: NPWT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPWT with sNAG in patients treated with antiplatelet drugs
Study: 23735352
Drug: N-acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (600 mg administered intravenously twice)
Study: 23735352
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (500 mg administered intravenously twice)
Study: 8712143
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 to 10 mg every morning)
Study: 8712143
Drug: Diltiazem-sustained release
Normalized name: diltiazem Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem-sustained release (90 to 180 mg twice daily)
Study: 1940058
Drug: AZT 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT 0.5 g/day p.o.
Study: 1940058
Drug: AZT 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT 0.5 g/day p.o. plus IVIG 0.4 g/kg for three consecutive days, followed by 0.6 g/kg every fourth week
Study: 1940058
Drug: AZT 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT 0.5 g/day p.o. and IVIG
Study: 1940058
Drug: AZT 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT 0.5 g/day p.o. plus IVIG
Study: 8925582
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo capsules
Study: 9205768
Drug: Ebrotidine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebrotidine 400 mg and ranitidine 300 mg combined with amoxicillin 750 mg and metronidazole 500 mg for 14 days
Study: 9205768
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving the same treatment
Study: 3096723
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg kg‐1
Study: 31148473
Drug: Simple Daily
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple Daily Sweepstakes
Study: 31148473
Drug: Wireless-enabled pill
Normalized name: Enablex Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wireless-enabled pill bottle and daily reminder messages
Study: 26418007
Drug: Low contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low contrast volume group (0.75 ml/kg)
Study: 26418007
Drug: Routine contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine contrast volume group (1.5 ml/kg)
Study: 20646266
Drug: Conservative strategy
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative strategy with antibiotics: hospital admission, supportive measures, and at least 48 hours of intravenous antibiotics switched to oral for a total duration of 10 days.
Study: 20646266
Drug: Liberal strategy
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal strategy without antibiotics: admission only if needed on clinical grounds, supportive measures only.
Study: 20646266
Drug: Both strategies
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both strategies (antibiotics and no antibiotics)
Study: 12411537
Drug: CHO (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (1 g (kg body mass)(-1) glucose 75 min prior to exercise)
Study: 30111065
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine combined with noninvasive ventilator therapy (Control group)
Study: 27311495
Drug: Buprenorphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (5 μg/h, titrated to a maximum of 40 μg/h)
Study: 24833354
Drug: VMP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMP plus siltuximab (11 mg/kg every 3 weeks)
Study: 17594199
Drug: Neither drug
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither drug (5 patients)
Study: 17594199
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (zidovudine plus TMP-SMX)
Study: 12401599
Drug: Ondansetron 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.15 mg/kg, maximum 4 mg (Group 1)
Study: 12401599
Drug: Dolasetron 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron 0.5 mg/kg, maximum 25 mg (Group 2)
Study: 10023504
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg i.v. clomipramine
Study: 10023504
Drug: 10-week oral
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10-week oral clomipramine
Study: 10023504
Drug: 10-week oral
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10-week oral fluvoxamine
Study: 1955308
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg yohimbine per os 4 times a day for 3 weeks
Study: 1955308
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg yohimbine per os
Study: 29883769
Drug: Oral omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral omega-3 (ω3) supplementation
Study: 24914003
Drug: Soapy water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soapy water (30 g powdered detergent in 1.5 L water)
Study: 21993999
Drug: Electronic alerts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic alerts recommending performance of an electrocardiogram and administration of aspirin for high risk patients (FRS ≥ 10%)
Study: 17324155
Drug: Low-dose doxycycline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose doxycycline (LDD) for 3 months
Study: 9715839
Drug: Acute methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute methadone treatment
Study: 9715839
Drug: Chronic methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic methadone treatment
Study: 1107769
Drug: Alprenolol slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprenolol slow-release formulation (Aptin Durules) 400-800 mg per day
Study: 1107769
Drug: Alprenolol ordinary
Normalized name: alprenolol
DrugBank: Alprenolol (DB00866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprenolol ordinary tablets (Aptin) 400 mg per day
Study: 1107769
Drug: Alprenolol slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprenolol slow-release formulation (Aptin Durules) double dosage
Study: 31464960
Drug: DEX (1 μg·kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX (1 μg·kg for 10 minutes, then adjusted to 0.2‐0.7 μg·kg·hour)
Study: 31464960
Drug: DEX (0.5 μg·kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX (0.5 μg·kg for 10 minutes, then adjusted to 0.2‐0.7 μg·kg·hour)
Study: 31464960
Drug: Sufentanil (0.3 μg·kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (0.3 μg·kg for 10 minutes, then adjusted to 0.2‐0.4 μg·kg·hour)
Study: 24127952
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg vaginal progesterone daily until delivery
Study: 18494605
Drug: Interleukin-10 (IL-10)
Normalized name: non-viral human interleukin-10 (IL-10) variant (IL-10var) encoding plasmid deoxyribonucleic acid (pDNA)
DrugBank: Interleukin-10 (DB12880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-10 (IL-10) concentrations > or = 37 pg/mL
Study: 18494605
Drug: Total protein
Normalized name: Total Protein Reagent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total protein concentrations > or = 674 mg/L
Study: 18494605
Drug: CSF WBC
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CSF WBC counts < or = 5 cells/microL (6 months after treatment)
Study: 18494605
Drug: CSF WBC
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CSF WBC count > or = 8 cells/microL and LATEX/IgM end titer > or = 1:4 (12 months after treatment)
Study: 18494605
Drug: CSF WBC
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CSF WBC count > or = 8 cells/microL and LATEX/IgM end titer > or = 1:4 (18 and 24 months after treatment)
Study: 17002722
Drug: Mebendazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (500 mg single dose) plus iron supplements (60 mg elemental iron daily)
Study: 16940835
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus iron supplements
Study: 8966351
Drug: dehydrobenzperidol (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: dehydrobenzperidol (1.25 mg)
Study: 8966351
Drug: placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (2 ml saline)
Study: 1342886
Drug: Micronized, freeze-dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized, freeze-dried DP extract in powder (active therapy)
Study: 1342886
Drug: Lactose capsules
Normalized name: lactose Oral Capsule
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose capsules (placebo group)
Study: 3871188
Drug: Prednisone 20
Normalized name: prednisone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 20 mg
Study: 31798892
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (matched by age, sex, and treatment arm)
Study: 22189593
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal spray (FP) 100 mcg twice daily as initial treatment with Fexofenadine hydrochloride tablet (FEX) 60 mg twice daily as additional treatment
Study: 22189593
Drug: Fexofenadine hydrochloride
Normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine hydrochloride tablet (FEX) 60 mg twice daily as initial treatment with Fluticasone propionate nasal spray (FP) 100 mcg twice daily as additional treatment
Study: 10511346
Drug: Combined estradiol‐progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined estradiol‐progestogen (2 mg estradiol + 0.5 mg trimegestone or 10 mg dydrogesterone)
Study: 10511346
Drug: Unopposed estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unopposed estradiol (2 mg)
Study: 31621936
Drug: Current use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current use of any antiepileptic drug
Study: 31621936
Drug: Current use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current use of any antiepileptic drug in individuals with a history of suicidal behavior
Study: 31621936
Drug: Current use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current use of any antiepileptic drug in individuals without a history of suicidal behavior
Study: 31621936
Drug: Current use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current use of any antiepileptic drug in individuals with a familial predisposition to psychiatric disorders
Study: 31621936
Drug: Current use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current use of any antiepileptic drug in individuals without a familial predisposition to psychiatric disorders
Study: 27672124
Drug: PF‐04236921 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐04236921 10 mg
Study: 27672124
Drug: PF‐04236921 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐04236921 50 mg
Study: 27672124
Drug: PF‐04236921 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐04236921 200 mg
Study: 23968157
Drug: CHF5074 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF5074 (600 mg/day)
Study: 23968157
Drug: CHF5074 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF5074 (200 mg/day)
Study: 23968157
Drug: CHF5074 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF5074 (400 mg/day)
Study: 23968157
Drug: CHF5074 (dose-dependent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF5074 (dose-dependent)
Study: 19142656
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (Cr) and Glycerol (Gly) supplementation (20 g Cr and 2 g Gly per kg body mass plus 2 l of water)
Study: 16489526
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan (200 mg/m(2)) and autologous blood stem-cell support
Study: 16489526
Drug: Cyclophosphamide (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (2-4 g/m(2)) and rhG-CSF
Study: 9032543
Drug: Sabal serrulata
Normalized name: Sabal Serrulata
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabal serrulata extract IDS 89 (Strogen) 320 mg/capsule, 3 x 2 capsules daily for 3 months
Study: 8495772
Drug: IVF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVF treatment (one cycle)
Study: 31786367
Drug: High vowel
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High vowel overlap training (e.g., EA, AI)
Study: 31786367
Drug: Low vowel
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low vowel overlap training (e.g., EE, AI)
Study: 28122649
Drug: L- and
Normalized name: Glycerol- and honey-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: L- and MZ-enriched eggs
Study: 15094102
Drug: Oral amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amino acid mixture (OAAM)
Study: 11922397
Drug: Promethazine (PRM)
DrugBank: Promethazine (DB01069)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Promethazine (PRM) 30 mg
Study: 11922397
Drug: Levocetirizine (L-CTZ)
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocetirizine (L-CTZ) 5 mg
Study: 11922397
Drug: Cetirizine (CTZ)
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine (CTZ) 10 mg
Study: 11922397
Drug: Loratadine (LOR)
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine (LOR) 10 mg